ARTICLE | Management Tracks
Consylman now at Vedere Bio II
Plus Neuron23 hires Jackson and updates from Sitryx, Illumina, Alto and more
April 12, 2022 11:06 PM UTC
Gina Consylman is now CFO at the vision restoration and preservation company Vedere Bio II, having resigned from bluebird bio Inc. (NASDAQ:BLUE) on March 25. Prior to bluebird, Consylman was CFO at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). Vedere is developing AAV-based gene therapies for inherited retinal degeneration and dry age-related macular degeneration.
Neuron23 Inc. hired Sam Jackson as CMO. The neuroimmunology company raised $100 million in a series C round last month. Jackson was SVP and CMO at Alector Inc. (NASDAQ:ALEC). Neuron23 is targeting LRRK2 and TYK2 to treat neurodegenerative and immunological diseases. ...